CA3107215A1 - Use of riluzole prodrugs to treat alzheimer's disease - Google Patents
Use of riluzole prodrugs to treat alzheimer's disease Download PDFInfo
- Publication number
- CA3107215A1 CA3107215A1 CA3107215A CA3107215A CA3107215A1 CA 3107215 A1 CA3107215 A1 CA 3107215A1 CA 3107215 A CA3107215 A CA 3107215A CA 3107215 A CA3107215 A CA 3107215A CA 3107215 A1 CA3107215 A1 CA 3107215A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- riluzole
- administered
- disease
- riluzole prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701814P | 2018-07-22 | 2018-07-22 | |
| US62/701,814 | 2018-07-22 | ||
| PCT/US2019/042718 WO2020023324A1 (en) | 2018-07-22 | 2019-07-20 | Use of riluzole prodrugs to treat alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3107215A1 true CA3107215A1 (en) | 2020-01-30 |
Family
ID=69181140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3107215A Pending CA3107215A1 (en) | 2018-07-22 | 2019-07-20 | Use of riluzole prodrugs to treat alzheimer's disease |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12161633B2 (https=) |
| EP (1) | EP3823616A4 (https=) |
| JP (2) | JP2021530543A (https=) |
| KR (1) | KR20210034621A (https=) |
| CN (1) | CN112469408A (https=) |
| AU (1) | AU2019310013B2 (https=) |
| BR (1) | BR112021000768A2 (https=) |
| CA (1) | CA3107215A1 (https=) |
| EA (1) | EA202190308A1 (https=) |
| IL (1) | IL280177B2 (https=) |
| MX (2) | MX2021000515A (https=) |
| NZ (1) | NZ772009A (https=) |
| PH (1) | PH12021550043A1 (https=) |
| SG (1) | SG11202100385YA (https=) |
| WO (1) | WO2020023324A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7805969B2 (ja) * | 2020-06-24 | 2026-01-26 | バイオヘイブン・セラピューティクス・リミテッド | 強迫性障害を治療するための組成物及び方法 |
| US20240016783A1 (en) * | 2020-10-05 | 2024-01-18 | Icahn School Of Medicine At Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
| AU2022222778A1 (en) * | 2021-02-22 | 2023-08-31 | Yale University | Targeted bifunctional degraders and methods using same |
| CN114344297B (zh) * | 2022-03-01 | 2024-05-14 | 暨南大学 | 利鲁唑在治疗少精症中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501875A (ja) * | 2000-06-14 | 2004-01-22 | メダレックス，インコーポレイティド | トリペプチドプロドラッグ化合物 |
| JP2008518935A (ja) * | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| CA2933464A1 (en) | 2013-12-09 | 2015-06-18 | Thomas Jefferson University | Use of abc drug efflux inhibitors in combination with anti-neurodegenerative drugs in the treatment of neurodegenerative disorders |
| KR102462638B1 (ko) * | 2014-11-26 | 2022-11-03 | 메디시노바, 인크. | 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법 |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| LT3458053T (lt) * | 2016-05-20 | 2022-02-25 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui |
| WO2018031707A1 (en) | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| TW202000205A (zh) * | 2018-02-21 | 2020-01-01 | 美商Ａｉ治療公司 | 使用阿吡莫德與麩胺酸性劑的組合治療 |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
-
2019
- 2019-07-20 MX MX2021000515A patent/MX2021000515A/es unknown
- 2019-07-20 EP EP19841953.3A patent/EP3823616A4/en active Pending
- 2019-07-20 EA EA202190308A patent/EA202190308A1/ru unknown
- 2019-07-20 CN CN201980048687.7A patent/CN112469408A/zh active Pending
- 2019-07-20 WO PCT/US2019/042718 patent/WO2020023324A1/en not_active Ceased
- 2019-07-20 IL IL280177A patent/IL280177B2/en unknown
- 2019-07-20 CA CA3107215A patent/CA3107215A1/en active Pending
- 2019-07-20 NZ NZ772009A patent/NZ772009A/en unknown
- 2019-07-20 SG SG11202100385YA patent/SG11202100385YA/en unknown
- 2019-07-20 US US17/261,057 patent/US12161633B2/en active Active
- 2019-07-20 KR KR1020217004639A patent/KR20210034621A/ko not_active Ceased
- 2019-07-20 AU AU2019310013A patent/AU2019310013B2/en active Active
- 2019-07-20 JP JP2021503571A patent/JP2021530543A/ja active Pending
- 2019-07-20 BR BR112021000768-7A patent/BR112021000768A2/pt unknown
-
2021
- 2021-01-07 PH PH12021550043A patent/PH12021550043A1/en unknown
- 2021-01-14 MX MX2024010655A patent/MX2024010655A/es unknown
-
2025
- 2025-02-21 JP JP2025026643A patent/JP2025093952A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3823616A1 (en) | 2021-05-26 |
| IL280177B1 (en) | 2024-09-01 |
| JP2021530543A (ja) | 2021-11-11 |
| US20210290599A1 (en) | 2021-09-23 |
| MX2024010655A (es) | 2024-09-11 |
| NZ772009A (en) | 2026-02-27 |
| AU2019310013B2 (en) | 2025-01-02 |
| BR112021000768A2 (pt) | 2021-05-11 |
| PH12021550043A1 (en) | 2021-09-20 |
| EP3823616A4 (en) | 2022-05-04 |
| WO2020023324A1 (en) | 2020-01-30 |
| IL280177A (en) | 2021-03-01 |
| KR20210034621A (ko) | 2021-03-30 |
| US12161633B2 (en) | 2024-12-10 |
| MX2021000515A (es) | 2021-06-08 |
| AU2019310013A1 (en) | 2021-02-11 |
| IL280177B2 (en) | 2025-01-01 |
| CN112469408A (zh) | 2021-03-09 |
| JP2025093952A (ja) | 2025-06-24 |
| EA202190308A1 (ru) | 2021-05-19 |
| SG11202100385YA (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12161633B2 (en) | Use of riluzole prodrugs to treat alzheimer's disease | |
| US11123332B2 (en) | Gaboxadol for reducing risk of suicide and rapid relief of depression | |
| Growdon et al. | Piracetam combined with lecithin in the treatment of Alzheimer's disease | |
| Reid et al. | A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence | |
| EP4277624B1 (en) | Troriluzole for use in the treatment of alzheimer's disease of mild severity | |
| CN116585316A (zh) | 包含pde9抑制剂的药物组合物 | |
| TW202339763A (zh) | 用於治療多種疾病之組成物及方法 | |
| KR20150119089A (ko) | 알츠하이머병 치료 방법에 사용하기 위한 헬리카제-프리마제 억제제 | |
| US12201618B2 (en) | Use of riluzole prodrugs to treat Alzheimer's disease | |
| US20240408086A1 (en) | Use of luvadaxistat for the treatment of cognitive impairment | |
| AU2023286504A1 (en) | Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc) | |
| EA049330B1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| US20250375459A1 (en) | Methods for ameliorating cognitive impairment using bile acid derivatives | |
| Ramos-Quiroga et al. | Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults | |
| Gracious et al. | Child and Adolescent Program of the 42nd Annual National Institute of Mental Health (NIMH) New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, Florida, June 10–13, 2002 | |
| Bhattacharyya et al. | P0361-Delta-9-tetrahydrocannabinol modulates parahippocampal and ventral striatal activity during processing of verbal memory | |
| DelaRaillere et al. | Bibliography Current World Literature Vol 15 No | |
| HK1252154B (zh) | 左乙拉西坦的延时释放药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250623 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250623 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20250916 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250917 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251119 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251119 |